Washington University

Disarm Therapeutics, Inc.

Aaron DiAntonio

Jeffrey D Milbrandt

Yo Sasaki

Kow Essuman

Xianrong Mao

Rajesh Devraj

Robert Owen Hughes

Raul Eduardo Krauss

Craig A Press

Dan Summers

Bradley R Miller

The present invention provides compounds useful as inhibitors of TIR NADase activity, compositions thereof, and methods of using the same. The present invention is useful for inhibition of TIR-domain NADase activity and/or treating microbial infection and/or modulating microbial physiology.

Identification of inhibitors of TcpC and TIR NADase activity

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

Inhibitors of SARM1 NADase activity and uses thereof

Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinase such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound.

Methods and compositions for inhibition of axonal degeneration by modulation of the DLK/JNK pathway

Growing community of inventors

Olivette, MO, United States of America

Aaron DiAntonio